Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 21:35 | 2026-03-16 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | Officer | OPT+S | $48.26 | 3,450 | $166,497 | 91,240 |
| 2026-03-17 21:37 | 2026-03-16 | CRSP | CRISPR Therapeutics AG | Prasad Raju | Officer | OPT+S | $48.26 | 9,869 | $476,278 | 13,773 |
| 2026-03-17 21:37 | 2026-03-16 | CRSP | CRISPR Therapeutics AG | Patel Naimish | Officer | OPT+S | $48.26 | 3,150 | $152,019 | 13,143 |
| 2026-03-16 20:03 | 2026-03-12 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | Officer | SELL | $2.55 | 10,076 | $25,684 | 515,427 |
| 2026-03-16 20:04 | 2026-03-12 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer | SELL | $2.55 | 7,043 | $17,953 | 507,261 |
| 2026-03-16 23:05 | 2026-03-12 | SRZN | Surrozen, Inc./DE | TCG Crossover GP II, LLC | 10% owner | BUY | $24.91 | 48,997 | $1,220,363 | 675,610 |
| 2026-03-14 00:59 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corporation | BOBULSKY SUSAN | Officer | SELL | $13.17 | 41,338 | $544,421 | 427,775 |
| 2026-03-14 00:55 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corporation | BENZENO SHARON | Officer | SELL | $13.17 | 63,103 | $831,067 | 272,751 |
| 2026-03-14 00:49 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corporation | ROBINS HARLAN S | Officer | SELL | $13.17 | 470,266 | $6,193,403 | 1,522,058 |
| 2026-03-14 01:36 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corporation | RUBINSTEIN JULIE | Officer | OPT+S | $13.21 | 179,703 | $2,374,056 | 507,934 |
| 2026-03-14 00:52 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corporation | PISKEL KYLE | Officer | SELL | $13.17 | 18,672 | $245,910 | 259,840 |
| 2026-03-14 01:02 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corporation | LO FRANCIS | Officer | SELL | $14.08 | 30,593 | $430,749 | 291,374 |
| 2026-03-14 00:45 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corporation | ROBINS CHAD M | Director, Officer | SELL | $13.17 | 470,167 | $6,192,099 | 2,301,113 |
| 2026-03-14 01:05 | 2026-03-11 | ADPT | Adaptive Biotechnologies Corporation | GRIFFIN MICHELLE RENEE | Director | SELL | $13.91 | 15,394 | $214,131 | 15,625 |
| 2026-03-14 00:00 | 2026-03-11 | APGE | Apogee Therapeutics Inc. | HENDERSON MICHAEL THOMAS | Director, Officer | SELL | $74.78 | 20,000 | $1,495,604 | 1,152,987 |
| 2026-03-13 22:43 | 2026-03-12 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.79 | 13,066 | $75,703 | 2,434,012 |
| 2026-03-13 20:30 | 2026-03-12 | PHGE | BiomX Inc. | Yeganeh Reuven | Director, 10% owner | SELL | $5.00 | 670,000 | $3,350,000 | 0 |
| 2026-03-12 20:51 | 2026-03-10 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer | OPT+S | $50.45 | 30,000 | $1,513,560 | 0 |
| 2026-03-12 20:05 | 2026-03-12 | LCTX | Lineage Cell Therapeutics, Inc. | Culley Brian M | Director, Officer | BUY | $1.63 | 15,000 | $24,375 | 255,516 |
| 2026-03-12 23:30 | 2026-03-10 | ALEC | Alector Inc. | Wong-Sarad Grace | Officer | SELL | $2.65 | 1,000 | $2,650 | 106,465 |
| 2026-03-12 22:17 | 2026-03-10 | RGNX | REGENXBIO Inc. | PAKOLA STEVE | Officer | SELL | $10.35 | 5,124 | $53,033 | 247,926 |
| 2026-03-12 21:35 | 2026-03-11 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | Director, Officer | OPT+S | $52.80 | 9,798 | $517,334 | 235,558 |
| 2026-03-12 21:35 | 2026-03-11 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | Officer | OPT+S | $52.80 | 2,800 | $147,840 | 87,815 |
| 2026-03-11 20:11 | 2026-03-09 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | Officer | SELL | $2.54 | 479 | $1,215 | 525,503 |
| 2026-03-11 20:10 | 2026-03-09 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer | SELL | $2.54 | 247 | $626 | 514,304 |
| 2026-03-11 20:30 | 2026-03-09 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | Officer | SELL | $10.06 | 17,717 | $178,233 | 231,584 |
| 2026-03-11 21:41 | 2026-03-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Director, Officer | SELL | $3.35 | 28,298 | $94,660 | 2,262,085 |
| 2026-03-11 22:51 | 2026-03-11 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer | OPT+S | $83.30 | 25,758 | $2,145,672 | 68,052 |
| 2026-03-11 22:22 | 2026-03-09 | INKT | MiNK Therapeutics, Inc. | Ryan Barbara | Director | SELL | $14.70 | 1,500 | $22,052 | 20,406 |
| 2026-03-11 21:23 | 2026-03-10 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer | SELL | $58.88 | 7,395 | $435,440 | 166,818 |
| 2026-03-11 21:23 | 2026-03-11 | PCVX | Vaxcyte, Inc. | Cowan Elvia | Officer | OPT+S | $58.59 | 2,500 | $146,482 | 30,867 |
| 2026-03-11 12:30 | 2026-03-09 | ENTX | Entera Bio Ltd. | Germano Geno J | Director | BUY | $1.30 | 20,000 | $26,000 | 40,000 |
| 2026-03-10 22:47 | 2026-03-06 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.83 | 4,079 | $23,760 | 2,420,946 |
| 2026-03-10 20:06 | 2026-03-06 | TWST | Twist Bioscience Corp | WERNER ROBERT F. | Officer | SELL | $46.43 | 246 | $11,421 | 54,799 |
| 2026-03-10 20:05 | 2026-03-06 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $46.43 | 425 | $19,731 | 138,257 |
| 2026-03-10 20:05 | 2026-03-06 | TWST | Twist Bioscience Corp | Green Paula | Officer | SELL | $46.43 | 935 | $43,408 | 124,401 |
| 2026-03-10 20:05 | 2026-03-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | SELL | $46.43 | 2,423 | $112,490 | 860,629 |
| 2026-03-10 23:18 | 2026-03-09 | HALO | HALOZYME THERAPEUTICS, INC. | Caudill Cortney | Officer | OPT+S | $67.75 | 28,857 | $1,955,160 | 7,055 |
| 2026-03-11 01:45 | 2026-03-06 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | Officer | OPT+S | $3.26 | 2,090 | $6,813 | 173,999 |
| 2026-03-11 01:00 | 2026-03-09 | ADMA | Adma Biologics Inc. | Kestenberg-Messina Kaitlin M. | Officer | OPT+S | $15.63 | 10,096 | $157,800 | 466,600 |
| 2026-03-11 00:04 | 2026-03-06 | ADPT | Adaptive Biotechnologies Corporation | RUBINSTEIN JULIE | Officer | OPT+S | $14.90 | 81,342 | $1,211,736 | 643,471 |
| 2026-03-10 00:29 | 2026-03-05 | ADPT | Adaptive Biotechnologies Corporation | LO FRANCIS | Officer | SELL | $15.09 | 38,074 | $574,537 | 321,967 |
| 2026-03-09 22:12 | 2026-03-06 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Officer | OPT+S | $30.17 | 6,262 | $188,935 | 55,285 |
| 2026-03-09 22:15 | 2026-03-06 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Officer | SELL | $30.00 | 10,000 | $300,000 | 69,747 |
| 2026-03-09 21:15 | 2026-03-05 | MGX | Metagenomi Therapeutics, Inc. | Irish Jian | Director, Officer | SELL | $1.60 | 1,607 | $2,571 | 333,770 |
| 2026-03-09 21:16 | 2026-03-05 | MGX | Metagenomi Therapeutics, Inc. | Wein Matthew | Officer | SELL | $1.60 | 482 | $771 | 114,549 |
| 2026-03-09 21:16 | 2026-03-05 | MGX | Metagenomi Therapeutics, Inc. | Wapnick Pamela | Officer | SELL | $1.60 | 1,581 | $2,530 | 187,375 |
| 2026-03-09 21:00 | 2026-03-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Officer | OPT+S | $15.68 | 8,000 | $125,440 | 170,844 |
| 2026-03-09 13:14 | 2026-03-05 | ADMA | Adma Biologics Inc. | ELMS STEVE | Director | BUY | $15.53 | 14,000 | $217,420 | 2,045,730 |
| 2026-03-09 12:30 | 2026-03-05 | ENTX | Entera Bio Ltd. | Ellis Sean | Director | BUY | $1.23 | 10,000 | $12,300 | 188,098 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.